• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    12/12/23 1:22:22 PM ET
    $ACHV
    $ACLX
    $ADEX
    $ADTX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACHV alert in real time by email

    Shares of Johnson Controls International plc (NYSE:JCI) moved lower during Tuesday’s session following weak quarterly results.

    Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion (+2% organically), missing the consensus of $7.09 billion. Adjusted EPS of $1.05 (+6% Y/Y) below the consensus of $1.09, according to Benzinga Pro.

    Johnson Controls International shares fell 6.2% to $53.05 on Tuesday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Aditxt, Inc. (NASDAQ:ADTX) shares jumped 140.5% to $9.14 after the company entered into definitive agreement to acquire Evofem Biosciences.
    • C4 Therapeutics, Inc. (NASDAQ:CCCC) gained 57.5% to $1.8590 after the company announced a license and research collaboration with Merck to discover and develop degrader-antibody conjugates.
    • Candel Therapeutics, Inc. (NASDAQ:CADL) shares climbed 48% to $1.24 after the company announced it received FDA Fast Track Designation for CAN-2409 in pancreatic cancer.
    • Icosavax, Inc. (NASDAQ:ICVX) rose climbed 47.1% to $15.43 after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Concurrently, Icosavax released topline interim results for its Phase 2 study of IVX-A12, a combination virus-like particle (VLP) vaccine candidate targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
    • Clean Earth Acquisitions Corp. (NASDAQ:CLIN) gained 41.3% to $6.71. Clean Earth and Alternus Energy announced continuation of business combination close process.
    • Bruush Oral Care Inc. (NASDAQ:BRSH) shares rose 24.1% to $0.2022 after gaining over 5% on Monday.
    • Spectaire Holdings Inc. (NASDAQ:SPEC) gained 23.7% to $2.1286. Spectaire announced manufacturing financing agreement to enable mass production.
    • Gaotu Techedu Inc. (NYSE:GOTU) rose 18% to $3.4650.
    • IN8bio, Inc.(NASDAQ:INAB) gained 17.8% to $1.5080 after the company announced updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies.
    • Pineapple Financial Inc. (NYSE:PAPL) rose 13.9% to $2.29.
    • Intchains Group Limited (NYSE:ICG) gained 13.5% to $10.16.
    • Oil-Dri Corporation of America (NYSE:ODC) rose 12.2% to $66.09 following first-quarter results.
    • Hanryu Holdings, Inc. (NASDAQ:HRYU) shares surged 11.2% to $0.70 after jumping 40% on Monday.
    • CAVA Group, Inc. (NYSE:CAVA) gained 9.8% to $35.68.
    • Eagle Bulk Shipping Inc. (NYSE:EGLE) jumped 9.2% to $50.42. Star Bulk and Eagle Bulk Shipping announced plans to combine.
    • Blue Bird Corporation (NASDAQ:BLBD) shares rose 9.1% to $23.80 after the company reported better-than-expected financial results for its fourth quarter and increased its FY24 revenue forecast.
    • Digital Turbine, Inc. (NASDAQ:APPS) gained 7.8% to $6.58.

    Losers

    • Achieve Life Sciences, Inc. (NASDAQ:ACHV) shares fell 41.9% to $3.1686. Achieve Life Sciences said NDA Filing timing may be delayed to address FDA feedback on drug product candidate, Cytisinicline. Oppenheimer maintained Achieve Life Sciences with an Outperform and lowered the price target from $21 to $18.
    • Boqii Holding Limited (NYSE:BQ) fell 37.7% to $1.3824.
    • Green Giant Inc. (NASDAQ:GGE) declined 36.7% to $0.0962 as the company announced pricing of public offering.
    • SRIVARU Holding Limited (NASDAQ:SVMH) fell 30.3% to $0.4999 after jumping 20% on Monday.
    • Harbor Custom Development, Inc. (NASDAQ:HCDI) fell 26.8% to $0.4975. Harbor Custom Development voluntarily filed for protection under Chapter 11 Bankruptcy.
    • Assure Holdings Corp. (NASDAQ:IONM) shares fell 26% to $0.32 after climbing over 23% on Monday.
    • African Agriculture Holdings Inc. (NASDAQ:AAGR) declined 20% to $0.8747.
    • Adit EdTech Acquisition Corp. (NYSE:ADEX) fell 17.7% to $6.05.
    • Nogin, Inc. (NASDAQ:NOGN) fell 17.5% to $0.1402.
    • Bon Natural Life Limited (NASDAQ:BON) fell 17.1% to $0.4974.
    • Incannex Healthcare Inc. (NASDAQ:IXHL) declined 11.2% to $4.4201.
    • Hempacco Co., Inc. (NASDAQ:HPCO) shares fell 11.1% to $0.3598.
    • Oracle Corporation (NYSE:ORCL) fell 10.3% to $103.32. Oracle reported upbeat earnings for its second quarter, while sales missed estimates.
    • Clean Energy Fuels Corp. (NASDAQ:CLNE) dipped 10.1% to $3.2550.
    • Clearmind Medicine Inc. (NASDAQ:CMND) fell 9.1% to $2.7650. Clearmind Medicine filed for mixed shelf of up to $50 million.
    • Lucid Group, Inc. (NASDAQ:LCID) shares fell 8.8% to $4.2050. Lucid Group disclosed that CFO Sherry House is resigning to pursue other opportunities.
    • Arcellx, Inc. (NASDAQ:ACLX) fell 8.7% to $47.79. Needham reiterated Arcellx with a Buy and maintained a $65 price target.
    • GoPro, Inc. (NASDAQ:GPRO) declined 8.4% to $3.28. Morgan Stanley downgraded GoPro from Equal-Weight to Underweight and lowered the price target from $4 to $3.
    • SilverBow Resources, Inc. (NYSE:SBOW) dipped 7.7% to $27.65. SilverBow Resources announced the upsize and pricing of a previously announced underwritten public offering of its common by an affiliate of Strategic Value Partners, LLC.
    • Kinetik Holdings Inc. (NYSE:KNTK) shares fell 3.4% to $33.17. Kinetik reported the pricing of an upsized underwritten secondary offering of 6,500,000 shares of its Class A common stock by Apache Midstream LLC at a price of $31.50 per share.

     

    Now Read This: Don't Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts

     

    Get the next $ACHV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHV
    $ACLX
    $ADEX
    $ADTX

    CompanyDatePrice TargetRatingAnalyst
    Oracle Corporation
    $ORCL
    2/25/2026$185.00Perform → Outperform
    Oppenheimer
    CAVA Group Inc.
    $CAVA
    2/25/2026$85.00 → $88.00Outperform
    Telsey Advisory Group
    Arcellx Inc.
    $ACLX
    2/12/2026$82.00Buy → Neutral
    Rothschild & Co Redburn
    Oracle Corporation
    $ORCL
    2/9/2026Buy → Hold
    Melius
    Oracle Corporation
    $ORCL
    2/9/2026$180.00Neutral → Buy
    DA Davidson
    Kinetik Holdings Inc.
    $KNTK
    2/6/2026$43.00Buy → Hold
    Jefferies
    CAVA Group Inc.
    $CAVA
    2/5/2026$80.00Buy
    The Benchmark Company
    Oracle Corporation
    $ORCL
    2/4/2026$270.00 → $205.00Outperform
    BMO Capital Markets
    More analyst ratings

    $ACHV
    $ACLX
    $ADEX
    $ADTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amlan International and Elanco Collaborate on Japanese Educational Seminars Focused on Calf Health

    CHICAGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America (NYSE:ODC), will collaborate with Elanco Animal Health on a three-day educational seminar in Japan from March 10–12 titled: "Creating the Future for Calves: Latest Clinical Approaches for Suckling Calves." The program will bring together veterinarians, producers, and industry stakeholders to exchange practical knowledge and field-based experience related to the management of diarrhea and pneumonia during the critical suckling period. In Japan, calf rearing is supported by careful daily observation, precise feeding management, and close veterinary involvement. Heal

    2/26/26 4:00:00 PM ET
    $ODC
    Miscellaneous manufacturing industries
    Consumer Discretionary

    Oracle Red Bull Racing Extends Title Partnership with Oracle in Multi-Year Deal to Power a New Era of Data-Driven Performance

    The most integrated F1 team technology partnership accelerates innovation, with Red Bull Ford Powertrains' power unit developed on Oracle Cloud Infrastructure and a ground-breaking AI-powered strategy agent launching trackside this seasonAUSTIN, Texas and MILTON KEYNES, England, Feb. 26, 2026 /PRNewswire/ -- Oracle and Oracle Red Bull Racing today announced a multi-year extension and expansion of their title partnership as the Team prepares for the most significant regulation shift in modern F1 history. This renewal builds on the most integrated team technology partnership in F1, with Oracle technology powering the Team's success and helping deliver a competitive advantage under pressure.

    2/26/26 8:00:00 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025 WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a cl

    2/26/26 7:00:00 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $ACLX
    $ADEX
    $ADTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oracle upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Oracle from Perform to Outperform and set a new price target of $185.00

    2/25/26 7:38:35 AM ET
    $ORCL
    Computer Software: Prepackaged Software
    Technology

    Telsey Advisory Group reiterated coverage on CAVA Group with a new price target

    Telsey Advisory Group reiterated coverage of CAVA Group with a rating of Outperform and set a new price target of $88.00 from $85.00 previously

    2/25/26 6:49:09 AM ET
    $CAVA
    Restaurants
    Consumer Discretionary

    Arcellx downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Arcellx from Buy to Neutral and set a new price target of $82.00

    2/12/26 7:20:24 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $ACLX
    $ADEX
    $ADTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Gilson Michelle sold $1,276,954 worth of shares (11,219 units at $113.82) and converted options into 20,530 shares, decreasing direct ownership by 23% to 33,938 units (SEC Form 4)

    4 - Arcellx, Inc. (0001786205) (Issuer)

    2/25/26 7:51:45 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Ellis Lindsay was granted 10,676 shares, increasing direct ownership by 33% to 43,093 units (SEC Form 4)

    4 - Kinetik Holdings Inc. (0001692787) (Issuer)

    2/24/26 6:11:59 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    Officer Stellato Steven was granted 20,226 shares, increasing direct ownership by 5% to 389,044 units (SEC Form 4)

    4 - Kinetik Holdings Inc. (0001692787) (Issuer)

    2/24/26 6:11:53 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    $ACHV
    $ACLX
    $ADEX
    $ADTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ACHV
    $ACLX
    $ADEX
    $ADTX
    SEC Filings

    View All

    Director Vergnano Mark bought $1,011,320 worth of Ordinary Shares (7,665 units at $131.94), gifted 7,665 units of Ordinary Shares and received a gift of 7,665 units of Ordinary Shares (SEC Form 4)

    4 - Johnson Controls International plc (0000833444) (Issuer)

    2/5/26 6:32:15 PM ET
    $JCI
    Industrial Machinery/Components
    Industrials

    Director Thau Daniel Mark bought $20,420 worth of shares (400 units at $51.05), increasing direct ownership by 7% to 6,099 units (SEC Form 4)

    4 - Blue Bird Corp (0001589526) (Issuer)

    12/5/25 9:28:38 AM ET
    $BLBD
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    CEO and President Schulman Brett exercised 36,657 shares at a strike of $5.79 and bought $7,347 worth of shares (150 units at $48.98), increasing direct ownership by 5% to 828,975 units (SEC Form 4)

    4 - CAVA GROUP, INC. (0001639438) (Issuer)

    11/12/25 4:30:15 PM ET
    $CAVA
    Restaurants
    Consumer Discretionary

    SEC Form S-8 filed by C4 Therapeutics Inc.

    S-8 - C4 Therapeutics, Inc. (0001662579) (Filer)

    2/26/26 7:51:54 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by C4 Therapeutics Inc.

    10-K - C4 Therapeutics, Inc. (0001662579) (Filer)

    2/26/26 7:49:37 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    C4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - C4 Therapeutics, Inc. (0001662579) (Filer)

    2/26/26 7:09:49 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHV
    $ACLX
    $ADEX
    $ADTX
    Leadership Updates

    Live Leadership Updates

    View All

    Digital Turbine Appoints Ben John as Chief Technology Officer

    The seasoned AI, Data, and AdTech veteran joins DT from Microsoft AI Copilot to help lead the next phase of innovation, building on continuous momentum and performanceAUSTIN, Texas, Feb. 25, 2026 /PRNewswire/ -- Digital Turbine, the global leader in growth solutions for the mobile ecosystem, is excited to announce the appointment of Ben John as the company's Chief Technology Officer. Joining the company at a period of accelerating growth, Ben will lead DT's global engineering, product architecture, data-first scaling, and AI-driven development to support its momentum.Digital Turbine appoints Microsoft AI executive Ben John, an AI, Data, and AdTech veteran, as Chief Technology Officer.Ben's c

    2/25/26 8:55:00 AM ET
    $APPS
    Multi-Sector Companies
    Miscellaneous

    Johnson Controls signs agreement to acquire Alloy Enterprises, strengthening data center thermal management leadership

    Transaction aligned with Johnson Controls' strategy to unlock cooling innovation and accelerate the AI-based economyEnhances Johnson Controls' leading capabilities in the rapidly growing data center thermal segmentMILWAUKEE, Feb. 18, 2026 /PRNewswire/ -- Johnson Controls (NYSE:JCI), a global technology leader in energy efficiency, decarbonization, thermal management and mission-critical performance, has signed an agreement to acquire Alloy Enterprises, a Boston-based company specializing in a next-generation thermal management platform for high-performance data centers and other mission critical industrial applications. The move will expand Johnson Controls' leadership and capabilities in th

    2/18/26 4:30:00 PM ET
    $JCI
    Industrial Machinery/Components
    Industrials

    Lucid Announces Appointment of Neil Marsons as Senior Vice President of Supply Chain

    NEWARK, Calif., Feb. 9, 2026 /PRNewswire/ -- Lucid Group, Inc. (NASDAQ:LCID), maker of the world's most advanced electric vehicles, today announced Neil Marsons has joined the organization as the Senior Vice President of Supply Chain. Bringing more than 20 years of experience to the role, Marsons will be responsible for expanding and strengthening the company's global supply chain, as well as closely partnering across the organization to support production at the company's facilities in Arizona and Saudi Arabia. Previously, Marsons served as the Group Chief Procurement Officer

    2/9/26 10:49:00 AM ET
    $LCID
    Auto Manufacturing
    Industrials

    $ACHV
    $ACLX
    $ADEX
    $ADTX
    Financials

    Live finance-specific insights

    View All

    Kinetik Reports Fourth Quarter and Full Year 2025 Financial and Operating Results and Provides 2026 Financial Guidance

    Kinetik Holdings Inc. (NYSE:KNTK) ("Kinetik" or the "Company") today reported financial results for the quarter ended December 31, 2025. Kinetik reported net income including noncontrolling interest of $416.7 million and $525.9 million for the three and twelve months ended December 31, 2025, respectively. Kinetik generated Adjusted EBITDA1 of $252.1 million and $987.7 million, Distributable Cash Flow1 of $151.7 million and $620.5 million, and Free Cash Flow1 of $(12.0) million and $167.2 million for the three and twelve months ended December 31, 2025, respectively. Highlights Generated record full year Adjusted EBITDA1 of $987.7 million, despite a challenging operating environment an

    2/25/26 4:15:00 PM ET
    $KNTK
    Natural Gas Distribution
    Utilities

    CAVA Group Reports Fourth Quarter and Full Year Fiscal 2025 Results

    Full Year CAVA Revenue Growth of 22.5% Including Same Restaurant Sales of 4.0% 72 Net New CAVA Restaurant Openings During Fiscal 2025 Full Year CAVA Restaurant-Level Profit Margin of 24.4% CAVA Group, Inc. (NYSE:CAVA) ("CAVA Group" or the "Company"), the category-defining Mediterranean fast-casual restaurant brand that brings heart, health, and humanity to food, today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2025. "2025 marked a milestone year for CAVA as we continued to deliver on our mission of bringing heart, health, and humanity to food while scaling the business with a long-term, intentional focus. Our momentum and market shar

    2/24/26 4:10:00 PM ET
    $CAVA
    Restaurants
    Consumer Discretionary

    Lucid Announces Fourth Quarter and Full Year 2025 Financial Results

    Financial HighlightsDelivered 5,345 vehicles in Q4 and 15,841 vehicles in 2025; up 72% compared to Q4 2024 and up 55% compared to full year 2024Nearly doubled production year over year and in-line with 2025 annual production guidance of approximately 18,000 vehicles despite supply chain and tariff headwindsQ4 2025 revenue of $522.7 million, up 123% compared to Q4 2024, and annual revenue of $1,353.8 million, up 68% compared to full year 2024GAAP diluted net loss per share of $(3.62) in Q4 2025 and $(12.09) in full year 2025Ended the quarter with approximately $4.6 billion in total liquidity2026 production guidance of 25,000-27,000 vehiclesOperational HighlightsAchieved an eighth consecutive

    2/24/26 4:05:00 PM ET
    $LCID
    Auto Manufacturing
    Industrials

    $ACHV
    $ACLX
    $ADEX
    $ADTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gaotu Techedu Inc.

    SC 13G/A - Gaotu Techedu Inc. (0001768259) (Subject)

    11/27/24 6:02:40 AM ET
    $GOTU
    Other Consumer Services
    Real Estate

    SEC Form SC 13G filed by Arcellx Inc.

    SC 13G - Arcellx, Inc. (0001786205) (Subject)

    11/22/24 4:12:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care